GLP-1 Weight Loss Treatment in Fort Worth at DFWPMA

What Can GLP-1 Weight Loss Treatment in Fort Worth Help With?

GLP-1 weight loss treatment can help eligible adults with obesity or overweight accompanied by qualifying medical conditions reduce body weight, regulate appetite, and improve certain obesity-related metabolic risk factors. The extent of weight loss and associated health benefits depends on the medication, dose, treatment duration, and individual response.

At DFWPMA Fort Worth, medical weight management evaluations may help patients experiencing:

• Obesity: Excess body fat associated with increased health risks, commonly assessed using body mass index alongside other clinical measurements.
• Overweight With Medical Complications: Excess body weight accompanied by conditions such as hypertension, dyslipidemia, or Type 2 diabetes that may support eligibility for prescription weight management treatment.
• Difficulty Losing Weight: Limited weight reduction despite sustained efforts involving nutrition changes, physical activity, and other appropriate lifestyle interventions.
• Increased Appetite: Persistent hunger or difficulty feeling satisfied after meals, which certain weight management medications may help regulate.
• Insulin Resistance: Reduced insulin sensitivity frequently associated with excess body fat and metabolic dysfunction, which may improve with clinically meaningful weight loss.
• Type 2 Diabetes and Obesity: Coexisting conditions for which appropriately selected incretin-based medications may improve blood glucose control and support weight reduction.
• Metabolic Syndrome: A combination of metabolic risk factors, including abdominal obesity, elevated blood glucose, abnormal cholesterol levels, and high blood pressure.
• Weight-Related High Blood Pressure: Elevated blood pressure that may improve with sustained weight reduction, although antihypertensive treatment may still be necessary.
• Abnormal Cholesterol and Triglycerides: Lipid abnormalities associated with excess body weight that may improve with weight loss and appropriate medical management.
• Weight Regain After Previous Weight Loss: Difficulty maintaining a reduced body weight, which may warrant evaluation for long-term obesity treatment strategies.

Obesity is a chronic, complex disease influenced by biological, genetic, environmental, and behavioral factors. Hormones involved in hunger and satiety contribute to appetite regulation and can make sustained weight loss difficult even when patients make consistent lifestyle changes.

GLP-1 receptor agonists act on pathways involved in appetite and glucose regulation. By increasing feelings of fullness and reducing hunger, these medications can help eligible patients consume fewer calories and achieve clinically meaningful weight reduction.

Schedule an appointment to discuss obesity treatment, metabolic health, and GLP-1 medication eligibility at DFWPMA Fort Worth.

What GLP-1 Weight Loss Treatments Are Available at DFWPMA Fort Worth?

GLP-1 weight loss treatment evaluations at DFWPMA Fort Worth focus on determining medication eligibility, reviewing obesity-related health conditions, and developing individualized medical weight management plans. Dr. Gitana Staskus provides specialized endocrinology care to help patients understand available treatment options and the clinical considerations involved in prescription weight loss medications.

Depending on the patient’s body mass index, medical history, existing conditions, and treatment goals, medical weight management may include:

• Comprehensive Weight Management Evaluation: Review of weight history, previous treatment attempts, current medications, metabolic conditions, and obesity-related health risks.
• GLP-1 Medication Eligibility Assessment: Evaluation of whether the patient meets prescribing criteria for FDA-approved chronic weight management medications.
• Semaglutide Treatment Evaluation: Assessment of whether semaglutide, a GLP-1 receptor agonist approved in specific formulations for chronic weight management, is appropriate for an eligible patient.
• Tirzepatide Treatment Evaluation: Consideration of tirzepatide, a dual GIP and GLP-1 receptor agonist, for eligible patients requiring medical weight management.
• Medication Safety Screening: Review of relevant contraindications and precautions, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and other medication-specific risks.
• Individualized Medication Planning: Discussion of appropriate medication selection, gradual dose escalation, treatment tolerability, and monitoring requirements when pharmacotherapy is prescribed.
• Blood Glucose and Metabolic Monitoring: Assessment of glucose control, kidney function when indicated, and other metabolic measurements relevant to treatment safety and effectiveness.
• Nutrition and Protein Intake Guidance: Dietary recommendations supporting adequate nutrition, preservation of lean body mass, and sustainable weight management.
• Physical Activity and Resistance Exercise: Guidance on appropriate exercise to support cardiovascular fitness, muscle preservation, and long-term weight management.
• Medication Side Effect Monitoring: Evaluation of nausea, vomiting, constipation, diarrhea, dehydration, and other potential adverse effects associated with incretin-based treatment.
• Long-Term Weight Management Follow-Up: Periodic assessment of weight changes, treatment response, medication tolerability, and ongoing treatment needs.

Prescription GLP-1 weight loss medications are generally considered for adults with a body mass index of 30 or higher, or 27 or higher when at least one qualifying weight-related medical condition is present. Specific eligibility requirements vary by medication and indication.

Semaglutide and tirzepatide are both used in FDA-approved weight management formulations, but they are not identical medications. Semaglutide activates GLP-1 receptors, while tirzepatide activates both GIP and GLP-1 receptors. Both can produce substantial weight loss in eligible patients, although individual responses vary.

Clinical trials have demonstrated meaningful average weight reduction with these medications when combined with appropriate nutrition and physical activity. In major obesity trials, semaglutide 2.4 mg produced approximately 15% average weight loss over 68 weeks, while tirzepatide produced approximately 15% to 21% average weight loss over 72 weeks across studied doses. These figures represent trial averages, not guaranteed individual results.

Patients should use prescription weight management medications only under qualified medical supervision and obtain them through legitimate pharmacies. Unapproved or improperly compounded products may carry additional quality, dosing, and safety risks.

Looking for GLP-1 weight loss treatment in Fort Worth? Contact DFWPMA or call (903) 957-0082 to schedule an appointment with Dr. Gitana Staskus and discuss medical weight management and GLP-1 treatment eligibility.